S1 Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO
astegolimabCOPDNCT05037929
…D exacerbations (primary endpoint) was significantly lower with astegolimab Q2W vs placebo (adjusted rate reduction 15%; P=0.0494), but not…